

## Company Location

17301 N. Perimeter Dr, Suite 100  
Scottsdale, AZ 85255

## Contact Numbers

Tel: (480) 505-0540  
Fax: (480) 505-0545

## Contact 1

Joseph Koziak  
**Title:** Senior VP  
[jkoziak@isotechnika.com](mailto:jkoziak@isotechnika.com)

## Contact 2

Stephanie Gillis-Paulgaard  
**Title:** Director of Communications  
[sgillispaullgaard@isotechnika.com](mailto:sgillispaullgaard@isotechnika.com)

## Company Overview

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada, with additional operations in Scottsdale, Arizona. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery, development, and commercialization of novel immunosuppressive therapeutics for use in the prevention of organ rejection in transplantation and in the treatment of autoimmune diseases.

## Expertise

Number of Employees	77
PhD	18
MS	
Other Degreed	30





### Specific Scientists

1. Mark Abel, Ph.D.
2. Daniel J. Trepanier, Ph.D.
3. Derrick G. Freitag, Ph.D.

### Awards

1. Profit 100 - Fastest Growing Companies in Canada
2. Deloitte & Touche - Fast 50 Program in Canada
3. Deloitte & Touche - Fast 500 Program in N. America
4. Alberta Venture - Fastest 30 Growing Companies

## Core Competencies



## Products and Services

### Professional Services

**Which Services:** Drug Analysis

**Describe:** Analytical services on immunosuppressive drugs.

## Business Outlook

### Mission Statement

Isotechnika is a biopharmaceutical company that utilizes expertise in immunology to discover and develop novel immunosuppressive therapeutics that are safer and more effective than currently available treatments for improved patient benefit.

### Commercialization Strategy

The broad business strategy of Isotechnika is to build a robust pipeline of immunosuppressive drugs with improved safety profile and efficacy. To achieve this objective, the company will leverage its in-house expertise to expand its drug pipeline and

will seek in-licensing opportunities to build complimentary portfolio of products. To maximize benefits, the Company will develop drug candidates as far as possible and at least to Phase II trials and then evaluate partnering.





### **Problems**

Similar to other successful biopharmaceutical companies, Isotechnika is faced with the challenge of securing long term sources of capital to fund its drug pipeline expansion and to execute its business/commercialization strategies. Another problem is attracting and recruiting qualified scientists with the required areas of specialization as the Company continues to grow and expand its drug portfolio.

### **Competition**

Our competition is any company which has an immunosuppressive drug at a similar or advanced stage of development with a comparable mechanism of action or a drug in development which has the potential to reduce or eliminate the need for the class of drugs being developed by Isotechnika..

### **Needs and Interests**



### **Synergistic or Strategic Opportunities**

**Where would the best partners be located?** The best partners would ideally be located in North America in close geographical proximity to our Canadian and American operations. This would reduce cost and facilitate synergistic relationship building and communications.

**What kinds of partnerships are of interest?** Isotechnika would be interested in forming partnerships with companies with a shared focus on immunosuppression and which have the resources and expertise to assist in the development, approval and commercialization of Isotechnika's novel therapeutics. Isotechnika would be interested in out-licensing technologies which fall outside our strategic focus to potential partners.

**When would the company want to partner?** The Company would be interested in forming a strategic alliance when such a partnership would dramatically strengthen its ability to execute its business strategy and maximize benefit to the Company and its shareholders.

**Why would it be good for this company to partner?** Isotechnika has many areas of scientific and managerial expertise, however, partner companies can bring expertise in marketing, regulatory affairs, distribution, manufacturing as well as the financial resources necessary for the Company to advance its novel drugs to the market place.

**What kind of companies would be good partners?** Good potential partners for Isotechnika would be companies that are also leaders in immunosuppression and that are equally committed to the development and commercialization of safer and more effective therapeutics for use in transplantation and the treatment of autoimmune diseases. Ideal companies would already have a franchise in immunosuppression with approved drugs and the financial resources, expertise and motivation to partner with Isotechnika to advance its drug(s) to the market place.